These stocks will be great stories in the second half of 2017, and are significantly undervalued.
Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.
The company's shares were up 24% ahead of market's open on an FDA approval.
Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.